News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
595,281 Results
Type
Article (52399)
Company Profile (130)
Press Release (542741)
Multimedia
Podcasts (147)
Webinars (20)
Section
Business (156716)
Career Advice (2475)
Deals (29273)
Drug Delivery (144)
Drug Development (72020)
Employer Resources (161)
FDA (16196)
Job Trends (12685)
News (281729)
Policy (30881)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2683)
Academic (1)
Accelerated approval (37)
Adcomms (36)
Allergies (146)
Alliances (40186)
ALS (172)
Alzheimer's disease (1819)
Antibody-drug conjugate (ADC) (324)
Approvals (16354)
Artificial intelligence (531)
Autoimmune disease (170)
Automation (38)
Bankruptcy (319)
Best Places to Work (9734)
BIOSECURE Act (23)
Biosimilars (196)
Biotechnology (77)
Bladder cancer (161)
Brain cancer (60)
Breast cancer (629)
Cancer (4793)
Cardiovascular disease (427)
Career advice (2096)
Career pathing (39)
CAR-T (285)
CDC (65)
Celiac Disease (1)
Cell therapy (762)
Cervical cancer (37)
Clinical research (61642)
Collaboration (1627)
Company closure (4)
Compensation (1178)
Complete response letters (77)
COVID-19 (2785)
CRISPR (96)
C-suite (836)
Cystic fibrosis (144)
Data (6060)
Decentralized trials (2)
Denatured (34)
Depression (152)
Diabetes (500)
Diagnostics (5977)
Digital health (42)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (238)
Drug pricing (221)
Drug shortages (35)
Duchenne muscular dystrophy (244)
Earnings (64228)
Editorial (68)
Employer branding (20)
Employer resources (145)
Events (88158)
Executive appointments (932)
FDA (19358)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1401)
Gene editing (205)
Generative AI (44)
Gene therapy (640)
GLP-1 (1076)
Government (4372)
Grass and pollen (8)
Guidances (380)
Healthcare (16160)
HIV (63)
Huntington's disease (50)
IgA nephropathy (87)
Immunology and inflammation (294)
Immuno-oncology (66)
Indications (112)
Infectious disease (3064)
Inflammatory bowel disease (197)
Inflation Reduction Act (14)
Influenza (114)
Intellectual property (246)
Interviews (456)
IPO (14538)
IRA (58)
Job creations (3269)
Job search strategy (1718)
JPM (67)
Kidney cancer (17)
Labor market (84)
Layoffs (621)
Leadership (41)
Legal (7260)
Liver cancer (93)
Longevity (14)
Lung cancer (635)
Lymphoma (377)
Machine learning (40)
Management (54)
Manufacturing (768)
MASH (174)
Medical device (12049)
Medtech (12097)
Mergers & acquisitions (15762)
Metabolic disorders (1358)
Multiple sclerosis (153)
NASH (22)
Neurodegenerative disease (358)
Neuropsychiatric disorders (105)
Neuroscience (3107)
Neurotech (1)
NextGen: Class of 2026 (5374)
Non-profit (3784)
Now hiring (36)
Obesity (674)
Opinion (298)
Ovarian cancer (167)
Pain (203)
Pancreatic cancer (231)
Parkinson's disease (290)
Partnered (27)
Patents (498)
Patient recruitment (486)
Peanut (58)
People (48537)
Pharmaceutical (37)
Pharmacy benefit managers (33)
Phase 1 (18737)
Phase 2 (26766)
Phase 3 (21397)
Pipeline (5316)
Policy (341)
Postmarket research (2335)
Preclinical (7771)
Press Release (38)
Prostate cancer (244)
Psychedelics (57)
Radiopharmaceuticals (265)
Rare diseases (928)
Real estate (4727)
Recruiting (66)
Regulatory (23890)
Reports (42)
Research institute (2547)
Resumes & cover letters (411)
Rett syndrome (28)
RNA editing (17)
RSV (80)
Schizophrenia (159)
Series A (228)
Series B (179)
Service/supplier (8)
Sickle cell disease (101)
Special edition (26)
Spinal muscular atrophy (146)
Sponsored (47)
Startups (3085)
State (1)
Stomach cancer (21)
Supply chain (109)
Tariffs (101)
The Weekly (112)
Vaccines (1131)
Venture capital (99)
Weight loss (470)
Women's health (82)
Worklife (22)
Date
Today (153)
Last 7 days (666)
Last 30 days (2277)
Last 365 days (28988)
2026 (4001)
2025 (29225)
2024 (32636)
2023 (36457)
2022 (46795)
2021 (50506)
2020 (47767)
2019 (38963)
2018 (29489)
2017 (29383)
2016 (27842)
2015 (30549)
2014 (24106)
2013 (19975)
2012 (21312)
2011 (21661)
2010 (19655)
Location
Africa (747)
Alabama (75)
Alaska (6)
Arizona (252)
Arkansas (12)
Asia (35227)
Australia (6319)
California (10810)
Canada (2696)
China (963)
Colorado (422)
Connecticut (475)
Delaware (332)
Europe (84867)
Florida (1655)
Georgia (331)
Hawaii (4)
Idaho (44)
Illinois (789)
India (61)
Indiana (490)
Iowa (23)
Japan (427)
Kansas (111)
Kentucky (32)
Louisiana (20)
Maine (76)
Maryland (1349)
Massachusetts (7796)
Michigan (273)
Minnesota (571)
Mississippi (5)
Missouri (123)
Montana (17)
Nebraska (23)
Nevada (115)
New Hampshire (68)
New Jersey (2898)
New Mexico (20)
New York (2833)
North Carolina (1405)
North Dakota (8)
Northern California (5359)
Ohio (307)
Oklahoma (17)
Oregon (37)
Pennsylvania (2095)
Puerto Rico (19)
Rhode Island (35)
South America (1115)
South Carolina (67)
South Dakota (1)
Southern California (4208)
Tennessee (155)
Texas (1644)
United States (38050)
Utah (291)
Vermont (1)
Virginia (255)
Washington D.C. (78)
Washington State (857)
West Virginia (4)
Wisconsin (117)
Wyoming (1)
595,281 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
February 4, 2026
·
11 min read
·
Tristan Manalac
Alzheimer’s disease
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point
After covering the Alzheimer’s space through every high and low,
BioSpace
’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
December 2, 2025
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
January 19, 2026
·
7 min read
·
Ben Hargreaves
Neurodegenerative disease
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
January 14, 2026
·
5 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
October 30, 2025
·
2 min read
·
Annalee Armstrong
1 of 59,529
Next
